Standout Papers

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 ye... 2020 2026 2022 2024901
  1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (2020)
    Yanjun Zhang, Gang Zeng et al. The Lancet Infectious Diseases

Citation Impact

5 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
2 intermediate papers

Works of Minnan Yang being referenced

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
2020 Standout

Author Peers

Author Infectious Diseases ASZ Genetics Health Molecular Biology Last Decade Papers Cites
Minnan Yang 916 113 41 285 207 8 1.1k
A. M. Rambotti 1 3 258 103 13 832
Mordechai Goldberg 6 33 46 19 487
J. L. Pate 15 115 358 87 29 1.2k
Nadira Seepersadsingh 89 49 11 49 15 428
Ed Petkus 15 389

All Works

Loading papers...

Rankless by CCL
2026